The expiration of many biologic drugs patents has sparked biosimilar development and boosted the biosimilar market growth. Biosimilars are alternative versions of innovator biologic drugs. These are biological products that are similar replicas of the biopharmaceuticals that inspired them. Biosimilars are sometimes confused with the "biological generics" due to biopharmaceuticals' structural and manufacturing complexities. But biosimilars are rather unique molecules with limited data at the time of approval, and there are concerns about their safety and efficacy. Though they are less expensive drugs with comparable safety and toxicity profiles and no clinically meanin...
